Posts

Showing posts with the label rivaroxaban

CAD plus atrial fib: should we use aspirin plus anticoag?

Image
  A recent study found that aspirin was actually harmful in patients with chronic coronary syndrome who were at high atherothrombotic risk and were on long-term anticoagulation, in the AQUATIC trial (Assessment of Quitting versus Using Aspirin Therapy in Patients with Stabilized Coronary Artery Disease after Stenting Who Require Long-Term Oral Anticoagulation. a bit of a mouthful....) in this French study: see   aspirin plus anticoag NEJM2025  in dropbox, or DOI: 10.1056/NEJMoa2507532     -- "chronic coronary syndrome" is the new name for "stable coronary artery disease" Details : -- 872 adults were eligible who had documented chronic coronary syndrome with previous coronary stent implantation more than 6 months before enrollment, had features of high residual atherothrombotic risk, and were receiving an oral anticoagulant (either a direct oral anticoagulant DOAC or a vitamin K antagonist VKA) for any reason.     --inclusion criteria: high-ri...

atrial fibrillation: stopping anticoagulation 1 yr after ablation

A recent South Korean study found that some patients who had catheter ablation for atrial fibrillation were able to discontinue anticoagulation therapy, in the ALONE-AF trial (Anticoagulation One year after Ablation of Atrial Fibrillation in Patients with Atrial Fibrillation (see afib ablation stop anticoag after 1 yr JAMA2025 in dropbox, or doi:10.1001/jama.2025.14679) Details: -- 850 adults aged 19 to 80 were enrolled in this open-label randomized controlled trial from 2020 the 2023 at 18 hospitals in South Korea, with follow-up until 2025 -- All enrollees had atrial fibrillation (AF) with catheter ablation and were put on anticoagulation as per usual; they were in intermediate or high risk of thromboembolism with a CHA2DS2-VASc score of at least 1 for men or 2 for women -- All had at least one non-sex-related stroke risk factor as determined by their CHA2DS2-VASc score and no documented recurrence of atrial arrhythmia for at least one year after their catheter ablation for AF ...

edoxaban alone is better than with anti-platelet if atrial fibrillation and stable CAD

Image
  a recent randomized control trial found that in patients with stable coronary artery disease and atrial fibrillation (AF), monotherapy with the anticoagulant edoxaban was better than dual antithrombotic therapy with an added antiplatelet drug (see afib and stable CAD NEJM2024  in dropbox, or DOI: 10.1056/NEJMoa2407362)   Details : -- 1040 patients were enrolled in a multicenter, open-label, adjudicator-masked, randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with atrial fibrillation and stable coronary artery disease, in 18 sites in South Korea, with recruitment from  2019-2022     -- coronary artery disease (CAD) was defined as being previously treated with revascularization or managed medically         -- stable CAD was defined as having had a percutaneous coronary intervention (PCI) or CABG at least 6 months before enrollment or an...